Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial (NCT03634475) enrolled 12 participants, all of whom completed the study with none dropping out. The trial involved a single injection of a treatment called PP-001 directly into the eye (known as an intravitreal injection) and was designed to test it in people with chronic, non-infectious uveitis — a condition involving ongoing inflammation inside the eye. The trial used increasing doses across participants to look at how the treatment was tolerated. The reported data shows that the primary outcome being measured was the number of participants who experienced what are called "treatment emergent adverse events" — meaning any unwanted or unexpected health events that occurred after receiving the injection. According to the results reported on ClinicalTrials.gov, all 12 participants were counted in this measurement. However, the submitted data does not include a breakdown of how many participants, if any, actually experienced such events, or what those events were — only that 12 participants were assessed. No secondary outcome measure data was reported in the submitted results. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗ · Read the linked publication on PubMed (PMID 36325389) ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 2 Uveitis Trial, Completed
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are 18 years old or older
- You have been diagnosed with a long-term eye condition affecting the back, middle, or entire interior of the eye (called chronic posterior uveitis, intermediate uveitis, or panuveitis)
- You can be either male or female
Who may not be able to join:
- You are currently taking certain medications or receiving certain treatments that are not allowed under the trial's rules (confirm with trial site for the specific list)
- You are pregnant or currently breastfeeding
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Evaluation of Safety and Tolerability by Determining Treatment Emergent Adverse Events
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.